Treatment of benign prostatic hyperplasia with transurethral plasma kinetic enucleation of prostate

Objective To assess the feasibility of transurethral plasma kinetic enucleation of prostate(TUPKEP) for benign prostatic hyperplasia(BPH) by comparing changes in interleukin-6(IL-6) and C reactive protein(CRP) before and after different surgical procedures. Methods Sixty-four patients with BPH were included in this study.Of these patients,16 who underwent transurethral vapor-resection of the prostate(TUVP) served as TUVP group and 48 who underwent TUPKEP with the British Gyrus-PKS system served as TUPKEP.Their serum IL-6 and CRP levels were measured 2h before operation and 24 and 48h after operation by ELISA. Results No significant difference was found in serum IL-6 level between the two groups before operation(P>0.05).However,the serum IL-6 level was significantly higher in the patients after operation than before operation(P<0.05).The serum IL-6 level was significantly higher in TUVP group than in TUPKEP group 24 and 48h after operation((3.86±1.42)μg/L vs(2.27±1.15)μg/L,(1.07±1.03)μg/L vs(0.81±1.24)μg/L,P<0.05).No significant difference was found in serum CRP level in the patients before operation(P>0.05).However,the serum CRP level was significantly higher in the patients after operation than before operation(P<0.05).The serum CRP level was significantly higher in the TUVP group than in the TUPKEP group 24 and 48 h after operation((41.54±12.88)mg/L vs(30.29±10.14)mg/L,(72.57±16.85)mg/L vs(58.29±11.56)mg/L,P<0.05). Conclusion TUPKEP is more suitable than TUVP to BPH with less damages.